BioSpace News Archive

Biopharma and life sciences companies from around the globe provide updates on their pipelines and businesses.

Currently, research is still ongoing with regards to the link between COVID and POTS. However, this increasing number of cases and the unfamiliarity of COVID’s long-lasting effects leave a lot more for the researchers to unmask.

Charles River Laboratories will acquire Cognate BioServices in an $875 million cash deal that will significantly expand the company’s capabilities in the high-growth cell and gene therapy sector.

With the COVID-19 vaccine rollout underway and a renewed sense of hope stemming from an aggressive vaccine dispersal plan, a common question has begun to emerge.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the following upcoming investor conferences:.

The Everlywell COVID-19 Test Home Collection Kit DTC is now FDA-Authorized for sale directly to consumers online and on shelves at retailers, regardless of symptoms or known exposure

Conference call scheduled for 4:30 p.m. ET today - Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH Continues to Enroll - Phase 1 Trial Evaluating VK0214 Ongoing; Expect to Initiate Proof-of-Concept Trial in X-ALD Patients Mid-2021 - Balance Sheet Remains Strong; Year-End Cash Approximately $250 Million

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the Leerink 10 th Annual Global Healthcare Conference. Bruce Cozadd , chairman and chief executive officer, will provide an overview of the company and a business and financial update on Wednesday, February 24, 2021

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Kolosis BIO, LLC (Kolosis) announced today, in collaboration with MTF Biologics (MTF), the market release of Kore Fiber™, an exclusively processed demineralized cortical fiber allograft for Kolosis.